WATERS CORP /DE/
Waters (WAT) reported Q2 2026 revenue of $1.645 billion, above the top of guidance, with 9% organic growth and adjusted EPS of $3.05. Full-year 2026 guidance was raised to 7% to 9% organic revenue growth and adjusted EPS of $14.45 to $14.65. Management cited cost actions, FX headwinds, China DRG headwinds, and progress in acquired biosciences and diagnostics.
Waters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.
Waters (WAT) issued new Q3 and full-year 2026 revenue guidance and reported Q2 results showing higher sales but a shift to a net loss, according to the company. The article cites a 90-day return of 14.57% and 1-year total shareholder return of 44.69%. It discusses valuation versus a $413.26 fair value estimate and notes recurring revenue up 11% this quarter.
Over the past 7 days, alphai's AI scored 5 news stories mentioning WAT (WATERS CORP /DE/). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent WAT coverage spans earnings, insider activity and market movers.
In the last 30 days, WAT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.4M). The most active reporter was KUEBLER CHRISTOPHER A with 1 filing.
Raised full-year guidance and top-end beat suggest improving demand and integration execution, but FX and China DRG headwinds remain key swing factors.
Guidance raise plus detailed acquired-business and cost-action metrics likely supports a near-term positive repricing, with focus on China headwinds and execution of the 180-day revitalization plan.
Fresh guidance and Q2 results reset the valuation debate around fair value versus downside margin if margins or growth miss.
The filing discloses an insider sale, which can be read as mild negative sentiment but is not, by itself, a fundamental catalyst.
Raised guidance and product/integration updates are near-term positives, but GAAP losses and integration execution risk keep the risk-reward mixed.
alphai scores every news story that mentions WAT with an AI model for sentiment and relevance, and aggregates insider trades from WATERS CORP /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Waters (WAT) reported Q2 2026 revenue of $1.645 billion, above the top of guidance, with 9% organic growth and adjusted EPS of $3.05. Full-year 2026 guidance was raised to 7% to 9% organic revenue growth and adjusted EPS of $14.45 to $14.65. Management cited cost actions, FX headwinds, China DRG headwinds, and progress in acquired biosciences and diagnostics.
7 min readWaters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.
6 min readWaters (WAT) issued new Q3 and full-year 2026 revenue guidance and reported Q2 results showing higher sales but a shift to a net loss, according to the company. The article cites a 90-day return of 14.57% and 1-year total shareholder return of 44.69%. It discusses valuation versus a $413.26 fair value estimate and notes recurring revenue up 11% this quarter.
7 min readKUEBLER CHRISTOPHER A sold 3,626 shares of WATERS CORP /DE/ (WAT) at $397.94 ($1.44M total) on 2026-08-06.
2 min readWaters (WAT) reported Q2 sales of $1.65B versus $771M a year earlier, with net income turning to a $136M net loss. The company raised 2026 revenue guidance to $1.75–1.76B for Q3 and $6.42–6.48B for full year, citing 9% organic constant-currency growth and progress integrating acquired BD businesses, plus a new Xevo TQ Absolute XR IVD system.
6 min readWaters Corp reported 9% organic constant-currency growth in Q2 2026, citing strength in pharma and academic end markets and a 400 bps growth acceleration in newly acquired Biosciences and Diagnostic Solutions. The company raised 2026 organic revenue guidance to 7-9%, expects acquired businesses to exit 2026 at 6%+ growth, and projects mid-teens adjusted EPS growth with margin expansion.
7 min readWaters (NYSE:WAT) shares rose about 6% after Q2 revenue jumped to $1.645 billion, including $817 million from the BD Biosciences and Diagnostic Solutions acquisition. GAAP results showed a net loss of $136 million and basic EPS loss of $1.38, while free cash flow was $202 million. Organic revenue grew 7% reported and 9% constant currency.
4 min readWaters Corp (NYSE:WAT) shares rose about 5% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Waters posted adjusted EPS of $3.05 on revenue of $1.65B, with 7% organic growth. The company now expects 2026 adjusted earnings around $14.55 per share at the midpoint.
4 min readWaters Corp (WAT) reported Q2 2026 earnings call highlights, citing strong organic growth and raised guidance. Management said FX translation is expected to reduce full-year revenue by about 60 bps and EPS by $0.25. China headwinds persist in acquired businesses, while guidance implies ~4% constant-currency growth in Q4. Adjusted EBIT margin guidance stays at 28.2%.
7 min readWaters Corporation (NYSE:WAT) reported Q2 CY2026 revenue of $1.65 billion, up 113% year on year and 1.3% above estimates, with non-GAAP EPS of $3.05, 1.4% above consensus. It guided next-quarter revenue around $1.75 billion and expects 119% YoY growth. Adjusted operating margin fell to -3.7%.
6 min read
